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Abstract
Myocardial remodeling is a major contributor in the development of heart failure (HF) after myocardial infarction (MI).
Integrin-linked kinase (ILK), LIM-only adaptor PINCH-1, and a-parvin are essential components of focal adhesions (FAs),
which are highly expressed in the heart. ILK binds tightly to PINCH-1 and a-parvin, which regulates FA assembly and
promotes cell survival via the activation of the kinase Akt. Mice lacking ILK, PINCH or a-parvin have been shown to develop
severe defects in the heart, suggesting that these proteins play a critical role in heart function. Utilizing failing human heart
tissues (dilated cardiomyopathy, DCM), we found a 2.27-fold (p,0.001) enhanced expression of PINCH, 4 fold for a-parvin,
and 10.5 fold (p,0.001) for ILK as compared to non-failing (NF) counterparts. No significant enhancements were found for
the PINCH isoform PINCH-2 and parvin isoform b-parvin. Using a co-immunoprecipitation method, we also found that the
PINCH-1-ILK-a-parvin (PIP) complex and Akt activation were significantly up-regulated. These observations were further
corroborated with the mouse myocardial infarction (MI) and transaortic constriction (TAC) model. Thymosin beta4 (Tb4), an
effective cell penetrating peptide for treating MI, was found to further enhance the level of PIP components and Akt
activation, while substantially suppressing NF-kB activation and collagen expression—the hallmarks of cardiac fibrosis. In
the presence of an Akt inhibitor, wortmannin, we show that Tb4 had a decreased effect in protecting the heart from MI.
These data suggest that the PIP complex and activation of Akt play critical roles in HF development. Tb4 treatment likely
improves cardiac function by enhancing PIP mediated Akt activation and suppressing NF-kB activation and collagen-
mediated fibrosis. These data provide significant insight into the role of the PIP-Akt pathway and its regulation by Tb4
treatment in post-MI.
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Introduction
The integrin-linked kinase (ILK) is a major focal adhesion protein
which links integrin’s to actin and maintains a cell to extracellular
matrix interaction for diverse physiological processes including
embryonic development, growth, cellular proliferation, differentia-
tion and survival [1,2]. Widely expressed in various cell types and
tissues, ILK is known to form a tripartite complex with LIM-only
protein PINCH and Parvin. Originally thought as a kinase [3],
recent structural and genetic studies have indicated that ILK is a
pseudo-kinase which functions as a scaffold to bind various proteins
including the integrin b cytoplasmic tail, and the cytoskeletal
adaptors PINCH and parvin [4,5]. The high affinity interactions of
PINCH-1-ILK-a-Parvin (PIP) are particularly important because
they have been found in many cell types and are essential for focal
adhesions that link extracellular matrix and cytoskeleton. PINCH
has two isoforms, PINCH-1 and PINCH-2. Parvin has three
isoforms; a-, b-and c-Parvin. ILK, PINCH-1 and a/b-parvin are
highly abundant in the heart and play an important role in cardiac
function as suggested by a growing amount of evidences [2,6,7].
Notably, conditional ILK deletion in the mouse heart causes
spontaneous dilated cardiomyopathy (DCM) and sudden death at 6
to 12 weeks of age [8,9]. Cre expression driven by the muscle
creatine kinase promoter also resulted in efficient deletion of ILK
from skeletal muscle. Surprisingly, these mice showed no obvious
muscle defects and grew normally, although early death from DCM
precluded development of later defects in ilk2/2 skeletal muscle. The
DCM phenotype in ilk2/2 hearts is similar to mice with cardiac-
specific ablation of ß1 integrin [10] and focal adhesion kinase (FAK)
[11]. However, loss of ILK causes early spontaneous onset of DCM,
whereas ß1 integrin and FAK ablation causes DCM in response to
an applied cardiac stress, suggesting ILK is an effector of other
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critical signaling pathways beyond FA. In this regard, the serine/
threonine kinase Akt Ser473 phosphorylation was suppressed in ilk2/
2 [8] and PINCH1/22/2 [12]. The phosphorylation of Ser 473 of
Akt activates the kinase, which in turn transduces antiapoptotic
‘‘survival’’ signals in a number of cells, including cardiomyocytes
[13,14]. Given the data that PIP is critically involved in regulating
Akt Ser-473 phosphorylation [8], PIP and its pathway to Akt
activation are likely involved in mediating heart disease progression.
It is postulated that the activation of Akt and the consequent
inhibition of GSK-3 may protect cells from apoptosis. Therefore, Akt
activation in failing DCM hearts could be a protective antiapoptotic
mechanism. Since, animal-based studies have recently indicated that
Akt/PKB is critically regulated by ILK during cardiac function and
dysfunction [8,15,16] and that Akt activation is dependent on the
ILK/PINCH interaction [17], we hypothesized that the phosphor-
ylation of Akt Ser 473 might also be elevated in DCM hearts.
Interestingly, a study on myocardial infarction in mice showed that
thymosin b4 (Tb4), a monomeric G-actin protein, targets ILK-
PINCH-1 leading to the activation of Akt for cardiac protection after
ischemic insult [8,15,16]. A follow up study showed that Tb4 induces
adult epicardial progenitor cells mobilization and neovascularization
following cardiac injury [18]. However, the mechanistic relationship
between Tb4, ILK-PINCH-1 and cardiac protection still remain
undefined. Moreover, the complete profiling of ILK and its binding
partners, like PINCH-1 and Parvin are still not known in the failing
human heart (DCM) or in experimentally induced MI or pressure
overload (transaortic constriction, TAC) models. Herein, we report
the activation cascade of ILK, PINCH and Parvin complexes in
failing human hearts (DCM), and inmurine TAC and inMImodels.
Our data provide the first insight into the role of PIP in human DCM
in correlation with mouse MI or TAC model. We also show that
Tb4 treatment may target the PIP-Akt pathway and reduce
inflammatory mediators, thereby, providing cardiac protection in
the MI model. Importantly, we showed that Tb4 limits the cardiac
protection in an MI model in the presence of wortmannin, an Akt
inhibitors suggesting the critical role of Akt in relation to Tb4 during
cardiac protection.
Results
Expression of PIP in DCM human hearts
To determine the role of PIP in human DCM, we first examined
the ILK and PINCH-1 levels in non-failing (NF) and DCMor failing
(F) human hearts. NF hearts from six individual donors and F hearts
from nine DCM patients were used for the analysis. Our data
showed a 2.27-fold enhanced expression of PINCH-1 and 10.5 fold
increased expression of ILK in F human hearts in comparison to NF
human hearts (p,0.001) (Fig. 1). An actin-binding protein a-Parvin,
crucial for connecting the ILK/PINCH-1 complex to the actin
cytoskeleton [19], was also found to be elevated in the F hearts
(Figure 1 E). Additionally, we determined the expression levels of
PINCH-II and b-Parvin, which did not show any significant changes
in DCM hearts (Fig. 1 C and F).
Status of ILK and PINCH-1 complexes and AKT in F and
NF human hearts
In order to determine the level of the ILK and PINCH complex
separately during heart failure, we performed co-immunoprecip-
itation studies. The experiments determined the levels of the ILK/
PINCH-1 complex in both F and NF hearts. Based on the fact that
N-terminal ILK ARD binds to PINCH-1 whereas C-terminal ILK
kinase domain binds to a-Parvin and the three proteins form a
ternary complex in cells [19], we used a-Parvin antibody/a-Parvin
to effectively pull down the ILK/PINCH-1 complex – an
approach that was also previously reported to pull down ILK/
PINCH-1 in cardiomyocytes [13,14]. Consistent with Figure 1A,
the association of ILK with PINCH-1 was also significantly
elevated in the F human hearts (Figure 2). Our data showed that
both PINCH and ILK (1.8- and1.4-fold respectively, p,0.001)
complexes were significantly increased in all F hearts, compared to
NF hearts (Fig. 2 A). Note that because we used a-Parvin antibody
to pull down the ILK/PINCH complex, the data suggest that the
ternary PINCH-ILK-a-Parvin complex (PIP) is also elevated.
Akt is activated as a downstream consequence of growth factor
signaling through phosphoinositide-3 kinases, and activation of Akt
has been associated with protection from apoptosis in cardiac
myocytes [20]. Because progressive myocyte apoptosis may
contribute to heart failure, we examined the activation status of
Akt by western blotting with a phospho-specific (Ser 473) antibody
(Fig. 2B). We observed a marked increase in Akt phosphorylation in
F human hearts compared with NF hearts, but absolute protein
levels were invariant.
Expression of PIP and phosphorylation of Akt in
transaortic constriction (TAC) and myocardial infarction
model: Effect of Tb4 in MI
To determine the expression of the PIP complex in the TAC
model, we performed immuno-blot analysis using their specific
antibodies. Our data showed a significant up regulation of both
ILK, PINCH and a-Parvin protein after 4 weeks of TAC (Fig. 3 A
and B). Compared to sham, TAC mice showed a 3.16 fold
increase of ILK (38.4163.29 vs. 121. 5865.50, p,0.001), 2.79
fold for PINCH (32.8461.75 vs. 91.7362.93, p,0.001) and 4.43
fold increase in a-Parvin (39.4861.57 vs. 174.9464.97, p,0.001).
These data suggest that the PIP complex is also elevated in the
murine pressure overload model.
To determine the expression of ILK, PINCH-1 and a-Parvin
after MI, we performed immuno-blot analysis using their specific
antibodies. Our data showed a significant up regulation of ILK,
PINCH and a-Parvin protein after 7d post-MI (Fig. 3 C and F).
Compared to sham, MI mice showed a 3.82 fold increase of ILK
(38.7162.48 vs. 148.2461.87, p,0.01), a 3.48 fold increase of
PINCH-1 (31.2061.03 vs. 108.7362.51, p,0.001) and a 3.61 fold
increase in a-Parvin (29.5862.54 vs. 107.9463.91, p,0.001). In
order to assess the role of Tb4 in regulating the PIP complex, Tb4
was injected into the myocardium and we observed a further
elevation of both ILK (148. 7362.51 vs. 166.7161.41) and
PINCH-1 (108.7362.51 vs. 135.2461.73) proteins (Fig. 3 D and
F) but no further elevation of a-Parvin. Additionally, we
determined the phosphorylation of Akt (Ser473) in MI mice
treated with Tb4. The data are shown in Fig. 3E and F. We
observed a 2.98 fold increase in Akt (Ser473) phosphoryla-
tion (21.7560.69 vs. 65.0261.48, p,0.001) in MI mice which
increased an additional 1.61-fold after Tb4 treatment (65.0261.48
vs. 105.2761.49) compared to non-treated MI mice.
Effect of Tb4 on cardiac function
Infarct size was evaluated in sham, MI, MI+Tb4, and
MI+Tb4+ wortmannin groups 7 days post-MI (n= 5) by
measuring the percent area of infarction in axial sections prepared
with Masson’s trichrome. Analysis demonstrated smaller infarct
sizes in Tb4 treated MI animals compared to MI only (1563% vs.
2563%, # p= 0.02). Furthermore, treatment with wortmannin in
addition to Tb4, abrogated the infarct attenuating effects of Tb4
resulting in infarct areas comparable to MI (2663% vs. 2563%,
*p= 0.69, Fig. 4A, 4B). Moreover, western blot analysis showed a
significant inhibition of pAkt (Ser473) in MI+Tb4+ wortmannin
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groups (Fig. 4C) indicating that wortmannin prevented Akt
phosphorylation.
Additionally, we assessed cardiac function in sham, MI,
MI+Tb4, and MI+Tb4+ wortmannin groups via transthoracic
echocardiography before and 7 days after MI. There were no
differences between groups prior to MI. Non-treated MI mice had
the greatest decrease in cardiac function and increase in LV mass
compared to sham operated mice (ejection fraction (EF),
0.1460.06 vs. 0.8760.03, p,0.01; end diastolic dimension
(EDD), 5.660.4 mm vs. 3.260.2 mm, p,0.01; LV mass (LVM),
178.5612.2 mg vs. 87.768.9 mg) (Fig. 4D–H). Mice receiving
Tb4 had a significantly improved cardiac function compared to
Figure 1. ILK and its associated protein levels in F and NF hearts. A Expression of ILK, PINCH-1, PINCH-II, a-Parvin, b-Parvin, and ILK in NF and
F human left ventricular lysates. GAPDH was the loading control. Six NF hearts and nine F hearts were used for all proteins except for PINCH-1 (12 F
hearts). Shown here are representative examples of these samples. Note that two representative gels from two different runs were shown for PINCH-1
and PINCH-II respectively. Also, in some of the F hearts, there exists a higher molecular weight band above PINCH-II. The origin of the band is not
clear. B–F Quantitation of protein expression in the F and NF hearts. (B) PINCH-1, (C) PINCH-II, (D) ILK), (E) a-Parvin, and (F) b-Parvin. *p,0.001 F vs. NF
(paired t-test), n = 6 for NF hearts and N= 9 for DCM hearts for PINCH-1 ILK and a-Parvin protein expression. p =n.s for PINCHII and b-Parvin protein.
doi:10.1371/journal.pone.0020184.g001
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untreated MI mice with Tb4 only treatment having the greatest
attenuating effect (EF, 0.5260.08 vs. 0.1460.06, p,0.01; EDD,
4.060.3 mm vs. 5.660.4 mm, p,0.05; LVM, 109.665.1 mg vs.
178.5612.2 mg, p,0.05) (Fig. 4D, 4E–H).
Treatment with wortmannin moderately attenuated the bene-
ficial effect of Tb4 in MI model. Compared to Tb4-treated mice,
wortmannin treated mice showed a slight decrease in ejection
fraction (0.5260.08 vs. 0.5060.02, p= 0.91) and fractional
shortening (0.2760.06 vs. 0.2160.01, p = 0.36) as assessed by
echocardiography (Fig. 4D, 4E–H).
Effect of Tb4 on NF-kB activation after MI
To find out the role of Tb4 in inflammation, we analyzed NF-
kB activation in 7d post-MI in mice treated with Tb4. An 8.14
fold NF-kB activation (11.760.84 vs. 95.2561.72, p,0.001) was
observed in 7d post-MI. Our data further indicate that Tb4
significantly reduces NF-kB activity in post-MI mice compared to
MI mice (95.2561.72 vs. 30.1061.91, p,0.001) (Fig. 5).
Effect of Tb4 on collagen expression after MI
To find out the role of Tb4 in cardiac fibrosis, we analyzed
collagen type I and type III mRNA expression in 7d post-MI
mice. Our data indicate that collagen type I (52.3561.6 vs.
123.8262.15, p,0.001) and type III (61.3661.7 vs. 18562.1,
p,0.001) were significantly upregulated in 7d post-MI mice. Fur-
thermore, Tb4 significantly reduces both collagen I (123.8262.15
vs. 67.0561.37, p,0.001) and collagen III (185.262.1 vs.
86.0361.5, p,0.001) expression compared to non-treated MI
mice. (Fig. 6A). Additionally, Masson’s trichome staining showed a
significant reduction in interstitial cardiac fibrosis in Tb4 treated
MI mice (Fig. 6B)
Discussion
The present study shows for the first time that the PIP complex
is associated with human DCM and in experimentally induced
heart failure mouse models like MI and TAC. Mechanistically, we
demonstrated that treatment with Tb4 in the MI model results in
significant improvement of cardiac function by suppressing NF-kB
and collagens synthesis, suggesting a potential use of Tb4 for
therapeutic intervention. LV remodeling is a complex process that
involves both infarcted and non-infarcted areas in the post-MI
myocardium resulting in LV dilation and ultimately heart failure.
In light of ILK’s role in cardiac pathologies, recent studies have
shown that transgenic mice with cardiac-specific over expression of
ILK exhibited compensated cardiac hypertrophy [21] whereas
ablation of ILK in mice caused more advanced cardiac failure [8].
These data strongly demonstrate that the ILK level is vital for the
control of cardiac function and dysfunction, and supports ILK as a
suitable target for therapeutics. The present study shows that ILK
is dramatically elevated in human DCM hearts further establishing
a potential role of ILK in heart failure. Importantly, we showed
that the ILK elevation was accompanied by an upregulation of its
partner molecule PINCH-1 and a-Parvin as well. The induction of
the PIP complex at this point may be evaluated as a consequence
of a stress or injury related phenomena where it acts as a signal to
regulate the remodeling process. This correlates with extensive cell
biology studies demonstrating a critical role of PINCH-1 in
controlling the ILK function in FA [13,17]. Since a-Parvin/ILK/
PINCH-1 is known as a major signaling platform within the
integrin-actin network [13], our results suggest a possibility that
PIP manipulation may lead to novel targets for heart disease.
Another finding of our study was the hyper-phosphorylation of
Akt/PKB in failing human hearts. Such a phenomenon was also
previously observed in another set of failing human hearts [22].
Furthermore, in ischemia reperfusion (I/R) and ischemic precon-
ditioning (IPC) settings in a rat model, Hausenloy DJ et al showed
that IPC protects the heart by phosphorylating the pro-survival
kinases Akt at reperfusion [23,24]. Our results corroborate the
recent animal model observations that have shown that ILK-
mediated Akt/PKB activation is a key pathway for mediating
cardiac dysfunction especially during heart failure and repair
[8,15,16]. Interestingly, Akt phosphorylation was not enhanced
during compensated hypertrophy in human hearts [25], suggesting
that the hyper-activation of Akt may be involved at the advanced
stages of heart failure like DCM. Akt has been implicated to in
receptor mediated signaling for survival or contractility of
myocytes [26,27] On the contrary, it has been reported that the
phosphorylation of Akt tends to decline in a canine model of
pacing induced heart failure [28]. The report showed that in early
pacing, both the Akt phosphorylation and kinase activity were
increased but were declined in the late pacing albeit both were
increased in comparison to sham [28]. The discrepancy is likely
due to the differing techniques to induce heart failure. We note
that although ILK acts as a pseudo-kinase that may not directly
phosphorylate Akt, recent studies have indicated that both PINCH
and a-Parvin are involved in regulating Akt signaling [29].
Specifically, PINCH was found to inhibit PP1alpha and promote
Akt activation [29] whereas a-Parvin was found to bind to Akt
[30] and possibly promote Akt activation by translocating Akt to
the plasma membrane [17]. The detailed pathogenesis of elevated
ILK and how its pathway to Akt may regulate human DCM
remain to be determined.
We have extended our study to the acute MI mouse model as
well as to the TAC model. Our data suggest that PIP complex
proteins are elevated in TAC mice suggesting their significant role
Figure 2. The interaction of ILK/PINCH-1 in failing (F) human
hearts. A Immunoprecipitation of the a-Parvin/ILK/PINCH-1 complex in
the F and NF human hearts. Extracts were immuno-precipitated with
anti-PARVA antibody 1D4 (a-P). Immuno-precipitated proteins were
immunoblotted with monoclonal anti-PARVA clone 3B5 antibody or
with monoclonal anti-ILK antibody and monoclonal anti-PINCH
antibody (Cell signaling, Inc). B. Phosphorylation of Akt Ser473 in
representative F and NF hearts. The total Akt level is shown below. Six
NF hearts and nine F hearts were used for all proteins except for PINCH-
1 (12 F hearts). Shown here are representative examples of these
samples. Results are presented as five different mice (n = 5).
doi:10.1371/journal.pone.0020184.g002
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in pressure induced or chronic heart failure. In an MI setting, our
data further showed an enhancement of the PIP complex in 7d
post-MI compared to non-MI hearts. We focused our study to the
MI as the remodeling occurs immediately in this setting, so that we
could assess the cardio-protective effect of Tb4. LV remodeling
after MI involves an alteration of cardiac geometry that include
functional, cellular and molecular changes [31] that ultimately
result in a deterioration of cardiac function. Post-infarction
remodeling occurs at both an early (within 72 hours) and a late
phase (beyond 72 hours) [32]. Therefore, a remodeling due to
injury has also been considered. To ascertain the role of Tb4 in
post-MI, our data show that Tb4 treatment further potentiates
both ILK and PINCH-1 levels but not a-Parvin-1 level and are
associated with improved cardiac function. Another study has
shown that ILK therapy was able to attenuate LV remodeling and
improve cardiac function after MI which partly corroborates with
Figure 3. Expression profile for PIP in TAC and MI. A. Individual PIP proteins were analyzed by Western blotting in mice 4 weeks after aortic
banding (AB) Upper panel shows the protein expression of Pinch-1, the middle panel shows ILK and the bottom panel shows a-Parvin. Actin is used
as a loading control. B. Quantification of panel A is shown on right side of panel A. The error bars represent the average 6 S.E. of five different mice
repeated in an independent experiments (n = 5, *p,0.001 compared to sham group, student t-test). Expression profile of PIP in MI and the effect of
Tb4 on MI. C. Western blot analysis of ILK, Pinch-1 and a- Parvin after 7 days post-MI. D. Western blot analysis of ILK, Pinch-1 and a- Parvin in Tb4
treated MI mice. E. Right panel shows western blotting analysis of Akt 473 phosphorylation as well as total AKT level in 7 days post-MI mice. F.
Quantification of blots from 3C, 3D and 3E are shown on right side of panel of 3E. Results are presented in five different mice (n = 5,* p,0.01
compared to sham or MI group, student t-test). The one way ANOVA test among the groups of MI and MI+Tb4 also showed significant at p,0.05
level.
doi:10.1371/journal.pone.0020184.g003
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our study in cardiac protection [33]. Tb4, the major actin
sequestering protein in eukaryotic cells, has several potential
clinical applications in the repair and remodeling of ulcerated
tissues and solid organs following hypoxic injuries, such as MI and
stroke [34]. Tb4 binds monomer actin in a 1:1 complex and acts
as a buffer, preventing polymerization into actin filaments and
maintaining a pool of actin monomers for use when filament
synthesis is necessary. Therefore, further upregulation of ILK and
Figure 4. Infarct size and Echocardiographic analysis of Tb4 and Tb4+ wortmannin treated MI mice. A. The percent infarct size 7 days
post-MI as determined by the epicardial infarct length divided by the epicardial left ventricle circumference in axial sections prepared with Masson’s
trichrome. The error bars represent the average 6 S.E. of five different mice in an independent experiments (#p= 0.02 and was significant when
compared MI vs. MI+Tb4, *p = 0.69 and considered as non-significant in one way ANOVA analysis when compared to MI vs. MI+Tb4+ wortmannin) B.
Representative is the images of hearts after MI in the presence and absence of Tb4 and wortmannin. C. Western blots analysis of phosphorylation of
Akt Ser473 in of Sham (WT), MI, Tb4 treated MI and MI+Tb4+ wortmannin treated mice of 7 days post-MI. The total Akt level is shown below. D. The
echocardiogram picture of Sham, MI, Tb4 treated MI and MI+Tb4+ wortmannin treated mice after 7 days of Tb4 treatment. E–H Quantification of LVH,
FSH, LVEDd and EF of the above mice after 7 days of MI. Results are presented in five different mice (n = 5, *p,0.001 compared to sham or MI group
at 7 days post-op, student’s t-test). The above parameters were not significant at day zero. The one way ANOVA test among the groups of MI and
MI+Tb4 also showed significant at p,0.05 level. The EF and FS in wortmannin +MI+Tb4 treated group showed non- significant (N.S) when compared
to MI+Tb4 group.
doi:10.1371/journal.pone.0020184.g004
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PINCH-1 in this study may be necessary to protect the
myocardium from excess actin polymerization. In addition, in a
separate study by Smart N et al, showed an induction of epicardial
neovascularization by Tb4 in the heart having the capacity to
sustain the myocardium after ischemic damage [35]. It is,
therefore, speculated that a long-term effect of Tb4 after MI
would be more effective. We are currently investigating whether
Tb4 has any role in cardiac mass prevention in the TAC model.
To get insight into the mechanism of Tb4 action in Akt
phosphorylation and PIP signaling, mice were treated with the Akt
inhibitor wortmannin in the presence of Tb4. Activation of PI3K/
Akt-dependent signaling has been demonstrated to protect cardiac
myocytes from I/R injury and to inhibit I/R-induced cardiac
myocyte apoptosis [36]. Treatment with wortmannin in addition
to Tb4 decreased the infarct size attenuating effects of Tb4
resulting in infarct areas comparable to MI only mice. However,
wortmannin treatment minimally attenuated the protective effects
of Tb4 on cardiac function in the acute infarct period one week
after MI, which is consistent with other studies that have shown
inhibition of Akt signal by wortmannin partially preventing the
favorable post-MI process in AT1A KO mice, but not in WT mice
[21]. This suggests that the beneficial effects of Tb4 on cardiac
function may not be solely dependent on increased Akt activation.
Increased Akt activation may be, in part, responsible for the
decreased infarct size seen which is directly related to myocyte
survival. It is also possible that Tb4 activating other signaling
pathway for cardiac protection like induction of epicardial
neovascularization to overcome the ischemic insult [35]. The
reason this did not translate into improved function may be
because the additional surviving myocytes in the Tb4 only vs.
Tb4+ wortmannin mice are recovering from ischemic injury in the
acute post-MI period and do not significantly contribute to overall
contractility [42]. Further studies comparing cardiac function in
the remote MI time period would help to determine if the
decreased infarct size in Tb4 only treated mice leads to improved
function over that of Tb4+ wortmannin treated mice.
It is also known that MI induces many inflammatory molecules
which further accelerate the adverse remodeling process and that
this inflammatory process is regulated by NF-kB [37]. Our data
showed that 7d post-MI activated NF-kB was significantly
inhibited by Tb4 treatment suggesting that Tb4 mediated cardiac
protection was partly due the inhibition of NF-kB activation.
Inhibition of NF-kB by Tb4 would provide additional support of
cardiac protection by reducing the inflammatory response. This is
the first report showing that Tb4 suppresses NF-kB activation in
an MI model. NF-kB, regulates various genes involved in
inflammatory responses and its activation is important for host
defense and repair following insult [38]. It is, therefore, more
Figure 5. Tb4 inhibits NF-kB translocation in MI mice. A. Mice were subjected to MI and Tb4 was injected and mice were kept for 7 days. NF-kB
activation was measured by gel mobility shift assay using 32p NF-kB DNA as a probe. Cold NF-kB DNA was used for competition analysis. A p65
antibody was used for super shift analysis. B. Semi-quantification of panel A is shown on right side of panel A. Results are presented as five different
mice (n = 5, *p,0.001 compared to sham or MI group, student’s t-test). The one way ANOVA test among the groups of MI and MI+Tb4 also showed
significant at p,0.05 level.
doi:10.1371/journal.pone.0020184.g005
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reasonable to speculate that the suppression of NF-kB activation is
a beneficial effect. Previously, we have shown that either knocking
down or complete inhibition of NF-kB significantly reduces
cardiac hypertrophy in an animal model [38,39]. It has also been
shown that application of Tb4 accelerates corneal re-epithelial-
ization and modulates corneal cytokine production in corneal
alkali injury model [40,41,42]. Tb4 has been shown to inhibit NF-
kB activation in TNFa stimulated corneal epithelial cells [43]
providing the evidence of anti-inflammatory function. Our data
are in agreement with the anti-inflammatory role of Tb4 after MI.
Furthermore, it has been suggested that Tb4 promotes angiogen-
esis, which would potentiate its therapeutic benefits in ischemic
insult [40,44].
We also observed reduced cardiac fibrosis post-MI following
Tb4 treatment. This suggests that Tb4 mitigates cardiac
remodeling by decreasing collagen I and III expression and
collagen deposition.
In conclusion, our study demonstrates for the first time the
complete expression profile of PIP proteins in human DCM
hearts, providing a greater understanding of the alteration of
cytoskeleton proteins during heart failure. We also show that Tb4
inhibits NF-kB activity and cardiac fibrosis after MI suggesting a
possible mechanistic pathway by which Tb4 aids in cardiac
function and repair in the setting of acute MI. As reported earlier,
Tb4 promotes corneal re-epithelialization, wound healing and cell
survival while regulating inflammation after trauma or surgery
without any significant side effects. It is of note that Tb4 has been
considered for a phase II clinical trial for acute MI by RegeneRx
pharmaceutical (http://www.regenerx.com) and more recently, a
randomized placebo controlled study was done in healthy
volunteers to examine the dose and toxicity effect. The data show
Tb4 to have no apparent toxicity effect, is well tolerated and is
under consideration to be used for acute MI [45]. In light of this
and our additional mechanistic insight into Tb4’s beneficial role in
cardiac protection, our findings also suggest its therapeutic
potential in acute MI.
Materials and Methods
Collection of Human Tissues
Non-failing (NF) human hearts were obtained from organ
donors whose hearts were not suitable for transplantation but who
had no history of cardiac disease. The hearts were from victims of
motor vehicle accidents (MVA), gunshot wounds or cerebral
vascular (CVA) accidents without any known hemodynamic
abnormalities. Failing human hearts (F) were obtained from
transplanted patients who had been diagnosed with DCM as
described previously [46]. Tissues from F human hearts were
collected at the time of transplantation and their clinical
parameters have been described in our previous publication
[46]. Ventricular tissues were frozen in liquid nitrogen for storage
at 280u. For determination of PIP expression, left ventricular
tissues were used. All studies involving human tissues were in
accordance with institutional guidelines and were approved by
research ethics committee as described previously [46]. All human
sample data were completed at the Cleveland Clinic. All animal
protocols were approved by the institutional review board (IRB) of
the Cleveland Clinic and follow up analysis of mice data were
performed at Texas A & M was approved by the Institutional
Biosafety Committee (IBC) and IACUC.
Figure 6. Tb4 attenuates cardiac fibrosis. A. Collagen type I and type III mRNA Expression was performed using their respective cDNA probes.
Quantification of panel A is shown on right side of panel A. Results are presented as five different mice (n = 5, *p,0.001 compared to sham or MI
group, student’s t-test). The one way ANOVA test among the groups of MI and MI+Tb4 also showed significant at p,0.05 level. B. Immuno-
histological analysis was performed by Masson’s trichome staining in MI and Tb4 treated MI mice.
doi:10.1371/journal.pone.0020184.g006
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Protein extracts and Western blot analysis
F and NF human hearts were washed with cold phosphate
buffered saline (PBS) and minced with a sterile blade. Total
protein was extracted using T-Per buffer from Pierce as previously
described [46]. Samples containing 60 mg of protein were
separated on 10% SDS-polyacrylamide gels and were electropho-
retically transferred onto PVDF membranes as described previ-
ously [46]. The antibodies used in this study including a-Parvin, b-
Parvin, and PINCH-1and II were provided by Dr Carry Wu.
pAkt, Akt, ILK and PINCH were purchased from Cell Signaling.
GAPDH or Actin antibody (Santa Cruz Biotechnology) was used
as an internal protein loading control.
Immunoprecipitation
Cytoplasmic extracts were made from left ventricular tissue
from F and NF human samples as described previously [46]. In
brief, left ventricular tissue from F and NF human samples were
homogenized in ice-cold hypotonic buffer (20 mM 4-(2- Hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.9;
10 mM KCl; 5 mM MgCl2; 0.1 mM EDTA, 0.1 mM ethylene-
glycotetraacetic acid (EGTA), 1 mM DTT, 1 mM PMSF, and
300 mM sucrose, with protease and phosphatase inhibitor
cocktail). The homogenate was incubated on ice for 20 min with
1% NP-40 and centrifuged. Supernatants containing cytoplasmic
proteins were collected and stored at 280uC. Approximately,
500 mg of pre-cleared cytoplasmic protein from each F and NF
human hearts was immune-precipitated with 5 mg of a-Parvin
antibody for 3 h at 4uC and then 20 ml of protein A/G Agarose
was added to each lysate and incubated at 4uC for 16 h. The
precipitate was collected by centrifugation at 5,000 rpm for 5 min
at 4uC. The pellets from each F and NF sample were washed three
times in lysis buffer (10 mM HEPES, pH 7.4, 250 mM NaCl, 1%
NP-40, 1 mM PMSF, and protease cocktail), and finally with
Laemmli buffer. Equal amounts of samples were loaded into 10%
SDS-PAGE gel and western blotting was performed by using ILK
and PINCH-1 antibody as a probe as described previously [46].
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using a double-stranded NF-kB binding
site oligonucleotide as a probe as described previously [47].
Myocardial Infarction Model
Acute myocardial infarction in C57BL6 mice was induced by
ligation of the left anterior descending artery (LAD) at 8 weeks of
age. Mice were anesthetized with intra-peritoneal injections of a
xylazine (5 mg/kg) and, ketamine (80 mg/kg) mixture, placed in a
supine position, and ventilated with a respiratory rate of 105
breaths/minute and a tidal volume of 0.25 mL at 60% oxygen.
Sternums were shaved, sterilized, and opened under a dissecting
microscope (Leica Model M500). Animals were intubated and
sternotomy was performed, and the proximal LAD was identified
with the use of a surgical microscope (Leica M500) after retraction
of the left atrium and ligated with 7-0 Prolene. Blanching and
dysfunction of the anterior wall verified LAD ligation. Animals
were divided into two groups: one that received an intra-cardiac
injection of Tb4 (500 ng/15 ml PBS) just after the ligation and the
control group that received PBS. Mice also received Tb4 (200 mg/
300 ml PBS) or 300 ml PBS intraperitoneally. Intraperitoneal
injections were given every day for 3 days following MI and then
tissues were collected for experimental use.
To examine the effect of Akt inhibition on Tb4 treatment, mice
were injected with the Akt inhibitor wortmannin (17 mg/kg body
weight) concurrently with the Tb4. Tissues were collected 1 week
post-MI for experimental use. Mice received Tb (200 mg/300 ml
PBS) or 300 ml PBS intraperitoneally. Intraperitoneal injections
were given the day of surgery, the following 2 days, and then days
5 and 7 following MI. Cardiac function was measured by
echocardiography before MI and 7 days post. The dose of
wortmannin was chosen following the protocol of Li Y et al and
Gao J et al [48,49].
Myocardial Infarct Size Measurement
One week after LAD ligation, mice were euthanized. The hearts
were flushed and fixed in 10% neutral buffered formalin. Fixed
hearts were embedded in paraffin and serially cut at 5 mm from
the apex to the level just below the coronary artery ligation.
Alternating sections were stained with Masson’s Trichrome.
Whole sections were imaged with the Pathscan Enabler IV Slide
Scanner (Meyer Instruments, Houston, TX). Infarct size was
determined by dividing the epicardial infarct length by the
epicardial left ventricle circumference.
Transaortic Constriction (TAC) model
Mice were anesthetized, intubated and placed on a ventilator as
stated above. A sternotomy was performed, and the transverse
aorta between the right sub-clavian and the left common carotid
arteries was isolated. A single 7-0 suture was placed around the
transverse aorta and tightened against a 27gauge needle placed
externally on top of the artery to provide a form. After tightening,
the needle was removed leaving the artery approximately 75%
occluded. Once banded, the sternum was closed using 6-0 silk
suture, and the skin was closed using 6-0 prolene suture. Any
residual pneumothorax was reduced using a 1 cc syringe with a
20G needle prior to closing the skin. The mice were then
ventilated for another 20 to 30 minutes, extubated, and then
placed in a prone position on fresh bedding. Sterility was
maintained throughout the procedure.
Determination of cardiac function data collection and
analysis
Echocardiography was performed using a Vivid 7 echocardi-
ography machine (GE Medical, Milwaukee, WI). LV mass and
velocity of the posterior wall were calculated by bullet equation
and tissue Doppler echocardiography (TDE) mode as described
previously [39].
Statistical Analysis
Data are expressed as mean (6 S.E). Differences between
experimental groups were evaluated for statistical significance
using Student’s t test. Differences with a value of p,0.001 were
considered significant in failing human hearts compared to non-
failing human heart. The values for cardiac function parameters
and infarct size were expressed as the mean 6 standard error of
mean (SEM). The statistical significance between Tb4 and
wortmannin treatment groups and those of the control group
were calculated by one-way ANOVA followed by Bonferroni’s
correction for multiple comparisons using PRISM 5 (GraphPad,
San Diego, CA). A p,0.05 were considered significant.
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